CFD 属于复杂的高风险金融工具,其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作,以及是否能够接受高额亏损的风险。

交易 Marker Therapeutics, Inc. - MRKR CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.025457%
空头隔夜费

Short position overnight fee


Margin. Your investment $1,000.00
隔夜费用 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
0.003235%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

Marker Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

关键数据
前收盘价* N/A
开仓* N/A
1 年变化* N/A
日范围* N/A
52 周范围 0.67-6.60
平均交易量(10 天) 4.03M
平均交易量(3 个月) 16.31M
市值 14.78M
市盈率 -100.00K
流通股 8.80M
收入 12.78M
EPS -2.96
股息(收益率 %) N/A
贝塔 0.87
下一个财报发布日期 Aug 9, 2023

所有数据都是由Refinitiv提供的, 除了标有星号的数据, 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平仓 Change Change (%) 開倉 High Low

Marker Therapeutics, Inc. Events

时间(协调世界时) (UTC) 国家/地区 事件
Tuesday, June 6, 2023

时间(协调世界时) (UTC)

13:00

国家/地区

US

事件

Marker Therapeutics Inc Annual Shareholders Meeting
Marker Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 9, 2023

时间(协调世界时) (UTC)

10:59

国家/地区

US

事件

Q2 2023 Marker Therapeutics Inc Earnings Release
Q2 2023 Marker Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, November 8, 2023

时间(协调世界时) (UTC)

10:59

国家/地区

US

事件

Q3 2023 Marker Therapeutics Inc Earnings Release
Q3 2023 Marker Therapeutics Inc Earnings Release

Forecast

-

Previous

-
查看所有活動
  • 年度
  • 每季度
2022 2021 2020 2019 2018
总收入 9.01354 1.24171 0.46679 0.21319 0.20599
总营业费用 39.1923 43.1263 29.3526 22.742 148.378
销售/一般/行政费用,总计 12.82 12.9248 10.4719 9.9772 24.3799
研究与开发 26.1393 27.7949 18.8808 12.7648 123.998
异常费用(收入) 0.23297 2.40658 0
营业收入 -30.1788 -41.8846 -28.8858 -22.5288 -148.172
利息收入(费用),非经营净值 0.24806 0.0057 0.17974 1.10084 0.21372
其他,净值
税前净收入 -29.9307 -41.8789 -28.7061 -21.428 -147.958
税后净收入 -29.9307 -41.8789 -28.7061 -21.428 -147.958
未计算非常项目前的净收益 -29.9307 -41.8789 -28.7061 -21.428 -147.958
净收入 -29.9307 -41.8789 -28.7061 -21.428 -147.958
普通股股东可获收益 (不含非经常性项目) -29.9307 -41.8789 -28.7061 -21.428 -147.958
普通股股东可获收益 (含非經常性項目) -29.9307 -41.8789 -28.7061 -21.428 -147.958
摊薄净收入 -29.9307 -41.8789 -28.7061 -21.428 -147.958
摊薄后加权平均股 8.351 7.65057 4.70399 4.55877 1.90919
扣除特别项目的每股摊薄盈利 -3.58408 -5.47396 -6.1025 -4.70038 -77.4976
每股正常摊薄盈利 -3.55619 -5.15939 -6.1025 -4.70038 -77.4976
收入 9.01354 1.24171 0.46679 0.21319 0.20599
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
总收入 4.73434 3.30914 3.94957 0.79051 0.96432
总营业费用 9.78657 7.27497 10.9689 10.0705 10.8779
销售/一般/行政费用,总计 2.51582 1.89382 3.67801 3.51518 3.733
研究与开发 7.27074 5.26706 7.2909 6.5553 7.02607
营业收入 -5.05223 -3.96583 -7.01933 -9.27997 -9.91363
利息收入(费用),非经营净值 0.08465 0.10941 0.09975 0.03579 0.00312
税前净收入 -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
税后净收入 -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
未计算非常项目前的净收益 -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
净收入 -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
普通股股东可获收益 (不含非经常性项目) -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
普通股股东可获收益 (含非經常性項目) -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
摊薄净收入 -4.96758 -3.85642 -6.91958 -9.24419 -9.91051
摊薄后加权平均股 8.72103 8.37358 8.35992 8.3592 8.31076
扣除特别项目的每股摊薄盈利 -0.56961 -0.46055 -0.82771 -1.10587 -1.19249
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.56961 -0.44692 -0.82771 -1.10587 -1.17819
收入 4.73434 3.30914 3.94957 0.79051 0.96432
异常费用(收入) 0 0.11409 0 0 0.11888
  • 年度
  • 每季度
2022 2021 2020 2019 2018
流动资产总额 16.6193 45.9822 24.4109 45.4866 61.9966
现金和短期投资 11.7822 42.3512 21.3524 43.9039 61.7467
现金等价物 11.7822 42.3512 21.3524 43.9039 61.7467
Prepaid Expenses 2.43508 2.48463 2.05792 1.52644 0.14172
Total Assets 34.4222 68.1351 45.6148 46.3593 62.1443
Total Current Liabilities 7.78181 12.9016 6.4018 1.99281 2.80357
Payable/Accrued 0.75561 3.04191 0.40401 0.44168 0.71957
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.5 1.14619 0 0.031 0.049
Total Liabilities 14.8211 24.1495 18.2702 2.27306 2.80357
Total Long Term Debt 0 0 0 0 0
Total Equity 19.601 43.9856 27.3446 44.0862 59.3407
Preferred Stock - Non Redeemable, Net
Common Stock 0.00841 0.08308 0.05073 0.04573 0.04544
Additional Paid-In Capital 447.642 442.021 383.533 371.574 365.401
Retained Earnings (Accumulated Deficit) -428.049 -398.118 -356.239 -327.533 -306.105
Total Liabilities & Shareholders’ Equity 34.4222 68.1351 45.6148 46.3593 62.1443
Total Common Shares Outstanding 8.4 8.31 5.07 4.57 4.54
应收账款总额,净额 2.402 0.00024 1 0.05619 0.10818
Property/Plant/Equipment, Total - Net 17.8029 22.1529 21.204 0.8727 0.14767
Property/Plant/Equipment, Total - Gross 23.0768 24.8931 21.7952 0.97817 0.14767
Accumulated Depreciation, Total -5.27386 -2.74014 -0.59126 -0.10547 0
Accounts Payable 1.612 5.144 2.935 0.993 1.619
Accrued Expenses 2.9142 3.56949 3.06279 0.52713 0.416
Other Liabilities, Total 7.03934 11.2479 11.8684 0.28025
Other Current Assets, Total 0 1.14619 0.00056
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
流动资产总额 10.9129 16.6193 22.4231 29.276 31.0175
现金和短期投资 6.40124 11.7822 18.0764 25.8217 28.6372
现金等价物 6.40124 11.7822 18.0764 25.8217 28.6372
应收账款总额,净额 2.08289 2.402 1.68102 0.62763 0.00219
Prepaid Expenses 2.42874 2.43508 2.66567 2.8267 2.19623
Total Assets 27.941 34.4222 41.1146 52.3197 54.9561
Property/Plant/Equipment, Total - Net 17.0282 17.8029 18.6915 23.0437 23.9386
Property/Plant/Equipment, Total - Gross 23.1203 23.0768 23.3627 26.9395 27.2547
Accumulated Depreciation, Total -6.09209 -5.27386 -4.67118 -3.89584 -3.31606
Total Current Liabilities 5.20405 7.78181 11.2868 13.4736 8.21451
Accounts Payable 2.863 1.612 2.021 1.767 5.016
Payable/Accrued 0.62397 0.75561 0.7174 0.66225 0.74068
Accrued Expenses 1.71708 2.9142 3.49845 3.04439 2.27597
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 12.0277 14.8211 18.5128 24.2935 19.2504
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.82365 7.03934 7.22599 10.8198 11.0359
Total Equity 15.9134 19.601 22.6017 28.0263 35.7058
Common Stock 0.0088 0.00841 0.0836 0.0836 0.08345
Additional Paid-In Capital 448.921 447.642 446.711 445.216 443.651
Retained Earnings (Accumulated Deficit) -433.017 -428.049 -424.193 -417.273 -408.029
Total Liabilities & Shareholders’ Equity 27.941 34.4222 41.1146 52.3197 54.9561
Total Common Shares Outstanding 8.8 8.4 8.36 8.36 8.35
Other Current Assets, Total 0 0 0 0.18186
Other Current Liabilities, Total 0 2.5 5.05 8 0.18186
Accounts Receivable - Trade, Net 1
  • 年度
  • 每季度
2022 2021 2020 2019 2018
净收入/起跑线 -29.9307 -41.8789 -28.7061 -21.428 -147.958
经营活动产生的现金 -26.9722 -27.2798 -20.0347 -18.2843 -14.4799
非现金物品 5.98266 6.9777 5.78745 5.52043 132.435
Cash Taxes Paid
已付现金利息
营运资金的变化 -5.81323 5.47242 2.39829 -2.48188 1.04252
融资活动产生的现金 0.20213 52.5559 6.73601 0.81648 71.245
融资现金流项目
股票的发行(报废),净额 0.20213 52.5559 6.73601 0.81648 71.245
债务的发行(退还),净额
现金净变化 -31.7152 22.145 -22.5516 -17.8428 56.6175
投资活动产生的现金 -4.94514 -3.13113 -9.25289 -0.37498 -0.14767
资本支出 -4.94514 -3.13113 -9.25289 -0.37498 -0.14767
经营活动产生的现金 2.78911 2.14898 0.48564 0.10512
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.96758 -29.9307 -26.0743 -19.1547 -9.91051
Cash From Operating Activities -5.8883 -26.9722 -20.6667 -13.0208 -12.2261
Cash From Operating Activities 0.81822 2.78911 1.976 1.15611 0.57633
Non-Cash Items 0.81343 5.98266 5.11359 3.64886 1.88857
Changes in Working Capital -2.55237 -5.81323 -1.68204 1.32896 -4.78045
Cash From Investing Activities -0.11261 -4.94514 -4.81779 -4.71843 -2.45219
Capital Expenditures -0.11261 -4.94514 -4.81779 -4.71843 -2.45219
Cash From Financing Activities 0.61997 0.20213 0.06357 0.06357 0
Issuance (Retirement) of Stock, Net 0.61997 0.20213 0.06357 0.06357 0
Net Change in Cash -5.38093 -31.7152 -25.4209 -17.6756 -14.6783

为什么选择 Capital.com?让我们的数字来说话。

Capital.com Group

535K+

交易者

87K+

每月活跃客户

$113M+

每月投资额

$64M+

每月提取金额

交易计算器

如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。

交易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投资
交易规模(杠杆 x 投资):
開倉

平仓

做空 做多

Marker Therapeutics, Inc. Company profile

关于 Marker Therapeutics Inc.

Marker Therapeutics, Inc.是一家处于临床阶段的免疫肿瘤学公司。 该公司专门从事基于T细胞的免疫疗法和基于肽的疫苗的开发和商业化,用于治疗血液恶性肿瘤和实体肿瘤的适应症。 公司从其MultiTAA特异性T细胞技术中开发出了领先的候选产品,该技术基于非工程化的肿瘤特异性T细胞的选择性扩增,这些T细胞能够识别肿瘤相关抗原(TAAs),这些抗原是肿瘤靶点,然后杀死表达这些靶点的肿瘤细胞。 该公司有三种MultiTAA特异性T细胞疗法通过临床开发,其中包括自体MultiTAA特异性T细胞疗法,异体MultiTAA特异性T细胞疗法和现成的MultiTAA特异性T细胞疗法。 公司专注于开发MT-601,用于治疗晚期不可切除的胰腺癌。

Industry: Biotechnology & Medical Research (NEC)

4551 Kennedy Commerce Dr.
HOUSTON
TEXAS 77032
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

71.98 Price
+2.450% 1D Chg, %
多头隔夜费 -0.0201%
空头隔夜费 -0.0018%
隔夜费时间 21:00 (UTC)
价差 0.04

Gold

1,948.36 Price
-1.480% 1D Chg, %
多头隔夜费 -0.0185%
空头隔夜费 0.0103%
隔夜费时间 21:00 (UTC)
价差 0.30

XRP/USD

0.53 Price
-0.060% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00433

US100

14,557.80 Price
+0.640% 1D Chg, %
多头隔夜费 -0.0255%
空头隔夜费 0.0032%
隔夜费时间 21:00 (UTC)
价差 3.0

还在找一位您可以信任的经纪商吗?

加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易